These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 22834825

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
    Brinkmann V.
    Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
    [Abstract] [Full Text] [Related]

  • 6. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets.
    Takabe K, Paugh SW, Milstien S, Spiegel S.
    Pharmacol Rev; 2008 Jun; 60(2):181-95. PubMed ID: 18552276
    [Abstract] [Full Text] [Related]

  • 7. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A.
    Neurology; 2011 Feb 22; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [Abstract] [Full Text] [Related]

  • 8. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
    Lee CW, Choi JW, Chun J.
    Arch Pharm Res; 2010 Oct 22; 33(10):1567-74. PubMed ID: 21052934
    [Abstract] [Full Text] [Related]

  • 9. Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells.
    Nagaoka Y, Otsuki K, Fujita T, Uesato S.
    Biol Pharm Bull; 2008 Jun 22; 31(6):1177-81. PubMed ID: 18520051
    [Abstract] [Full Text] [Related]

  • 10. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720.
    Kihara A, Igarashi Y.
    Biochim Biophys Acta; 2008 Sep 22; 1781(9):496-502. PubMed ID: 18555808
    [Abstract] [Full Text] [Related]

  • 11. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA, Chun J.
    Ann Neurol; 2011 May 22; 69(5):759-77. PubMed ID: 21520239
    [Abstract] [Full Text] [Related]

  • 12. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720.
    Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, van Echten-Deckert G, Hajdu R, Rosenbach M, Keohane CA, Mandala S, Spiegel S, Proia RL.
    J Biol Chem; 2004 Dec 10; 279(50):52487-92. PubMed ID: 15459201
    [Abstract] [Full Text] [Related]

  • 13. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
    Chun J, Hartung HP.
    Clin Neuropharmacol; 2010 Dec 10; 33(2):91-101. PubMed ID: 20061941
    [Abstract] [Full Text] [Related]

  • 14. Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2.
    Yoshino T, Tabunoki H, Sugiyama S, Ishii K, Kim SU, Satoh J.
    Cell Mol Neurobiol; 2011 Oct 10; 31(7):1009-20. PubMed ID: 21519925
    [Abstract] [Full Text] [Related]

  • 15. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720.
    Kharel Y, Lee S, Snyder AH, Sheasley-O'neill SL, Morris MA, Setiady Y, Zhu R, Zigler MA, Burcin TL, Ley K, Tung KS, Engelhard VH, Macdonald TL, Pearson-White S, Lynch KR.
    J Biol Chem; 2005 Nov 04; 280(44):36865-72. PubMed ID: 16093248
    [Abstract] [Full Text] [Related]

  • 16. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720.
    Hisano Y, Kobayashi N, Kawahara A, Yamaguchi A, Nishi T.
    J Biol Chem; 2011 Jan 21; 286(3):1758-66. PubMed ID: 21084291
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
    Baumruker T, Billich A, Brinkmann V.
    Expert Opin Investig Drugs; 2007 Mar 21; 16(3):283-9. PubMed ID: 17302523
    [Abstract] [Full Text] [Related]

  • 20. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
    Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hoyer D, Mir A.
    Pharmacol Ther; 2008 Jan 21; 117(1):77-93. PubMed ID: 17961662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.